Get the Stockscreener App
1.61
3.87%
0.06
After Hours:
1.61
In 8 Bio Inc stock is traded at $1.61, with a volume of 189.71K.
It is up +3.87% in the last 24 hours and down -3.01% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.55
Open:
$1.55
24h Volume:
189.71K
Relative Volume:
0.71
Market Cap:
$15.85M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-0.6056
EPS:
-2.6585
Net Cash Flow:
$-12.71M
1W Performance:
-12.50%
1M Performance:
-3.01%
6M Performance:
-22.97%
1Y Performance:
-75.34%
1-Day Range:
$1.50
$1.6599
1-Week Range:
$1.50
$2.03
52-Week Range:
$1.17
$6.66
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.61 | 15.26M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation - MSN
TELA Sees Growth with FY26 Revenue Projected to Rise at Least 8% - GuruFocus
TELA Bio (NASDAQ: TELA) lifts 2025 sales 16% but posts $38.8M loss - Stock Titan
Medical device maker secures up to $70M after 18% sales gain - Stock Titan
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - The Manila Times
INmune Bio will discuss 2025 results and corporate update March 30 - Stock Titan
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cabaletta Bio (NASDAQ: CABA) details 2025 results and advances rese-cel trials - Stock Titan
INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia - GlobeNewswire Inc.
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
TELA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
TELA Bio (TELA) hit with Nasdaq $1 bid-price deficiency, faces delisting risk - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event | BPTH SEC FilingForm 8-K - Stock Titan
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
[EFFECT] Gossamer Bio, Inc. SEC Filing - Stock Titan
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan
CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows noninvasive option - Stock Titan
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
INmune Bio Receives $8 Consensus Price Target from Analysts - National Today
KRRO SEC FilingsKorro Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
[8-K] Bio Green Med Solution, Inc. Reports Material Event | BGMS SEC FilingForm 8-K - Stock Titan
CyPath Lung growth accelerates while bioAffinity (NASDAQ: BIAF) posts larger 2025 loss - Stock Titan
Morgan Stanley Smith Barney files Form 144 to sell restricted KALA shares (KALA) - Stock Titan
Adicet Bio (NASDAQ: ACET) outlines 2025 loss and cash runway into 2027 - Stock Titan
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA) - Stock Titan
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BioXcel Therapeutics (NASDAQ: BTAI) completes $7.8M equity and warrant financing - Stock Titan
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028 - Stock Titan
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Climb Bio (Nasdaq: CLYM) ends 2025 with $160.7M cash and key 2026 trial readouts ahead - Stock Titan
KALA BIO (NASDAQ: KALA) signs exclusive Researgency AI license and $55M Younet option - Stock Titan
Bank license renewal backs BIO-key (NASDAQ: BKYI) biometric growth - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
bioAffinity Technologies (NASDAQ: BIAF) shows asthma and COPD diagnostic data - Stock Titan
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
Adicet Bio Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):